Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$17,189,552
New position
Shares Held
960,847
first reported quarter
Ownership
1.74%
of shares outstanding
% of Portfolio
1.90%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Octagon Capital Advisors LP holds $869,736,107 across 27 Biotechnology names. AKTS ranks #18 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,946,667 | $163,364,294 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
2,350,000 | $90,451,500 | |
| 3 | ABVX |
Abivax S.A.
|
677,000 | $75,383,950 | |
| 4 | ALMS |
Alumis Inc.
|
2,830,700 | $62,360,321 | |
| 5 | DFTX |
Definium Therapeutics, Inc.
|
2,440,000 | $46,116,000 | |
| 6 | AVBP |
ArriVent BioPharma, Inc.
|
1,971,054 | $45,472,215 | |
| 7 | TSHA |
Taysha Gene Therapies, Inc.
|
8,859,911 | $39,603,802 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
425,000 | $35,398,250 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $17,189,552 | 960,847 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||